Primary safety: 34.5% of participants experienced transient gastrointestinal adverse effects.
During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects.
Efficacy of berberine in patients with type 2 diabetes mellitus.
Evidence scope. Human, type 2 diabetes patients (not healthy volunteers); trial-specific adverse-event rate, not a general-population figure.